Emergent Biosolutions (EBS) : Traders are bullish on Emergent Biosolutions (EBS) as it has outperformed the S&P 500 by a wide margin of 17.85% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 10.99%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 11.18% in the last 1 week, and is up 17.21% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 13.96% and the 50-Day Moving Average is 9.97%.The 200 Day SMA reached 9.38%
Emergent Biosolutions (NYSE:EBS): After opening at $29.93, the stock dipped to an intraday low of $29.39 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $31.8 and the buying power remained strong till the end. The stock closed at $31.53 for the day, a gain of 13.58% for the day session. The total traded volume was 1,400,402. The stocks close on the previous trading day was $31.53.
Emergent Biosolutions (EBS) : 2 Wall Street analysts covering Emergent Biosolutions (EBS) believe that the average level the stock could reach for the short term is $40. The maximum price target given is $47 and the minimum target for short term is around $33, hence the standard deviation is calculated at $9.9.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Companys two operating divisions include Biodefense and Biosciences. The Companys Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) threats. The Biodefense divisions marketed products are BioThrax; BAT; Anthrasil; VIGIV, and RSDL. The Biodefense division investigational stage product candidates include NuThrax, PreviThrax, GC-072 and other biodefense product candidates. The Biosciences divisions marketed products are WinRho SDF, HepaGam B, VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY, ES414 and otlertuzumab.